Holen Sie sich die Stockscreener-App
15.95
2.77%
0.43
Handel nachbörslich:
15.75
-0.20
-1.25%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$15.52
Offen:
$15.75
24-Stunden-Volumen:
21.99M
Relative Volume:
2.04
Marktkapitalisierung:
$18.57B
Einnahmen:
$14.29B
Nettoeinkommen (Verlust:
$-3.51B
KGV:
-5.388
EPS:
-2.9603
Netto-Cashflow:
$1.85B
1W Leistung:
+6.55%
1M Leistung:
+18.94%
6M Leistung:
+57.76%
1J Leistung:
+88.09%
1-Tages-Spanne:
$15.52
$16.07
1-Wochen-Bereich:
$14.78
$16.07
52-Wochen-Spanne:
$8.19
$16.47
Viatris Inc Stock (VTRS) Company Profile
Firmenname
Viatris Inc
Sektor
Telefon
(724) 514-1465
Adresse
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, ZTS, TEVA, HLN, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
15.95 | 18.07B | 14.29B | -3.51B | 1.85B | -2.9603 |
TAK
Takeda Pharmaceutical Co Adr
|
16.72 | 52.28B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
111.22 | 47.33B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.34 | 41.76B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.23 | 40.70B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
596.76 | 24.28B | 3.18B | 1.33B | 1.04B | 27.90 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-09 | Hochstufung | UBS | Neutral → Buy |
| 2026-01-16 | Hochstufung | Argus | Hold → Buy |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-06-06 | Eingeleitet | Goldman | Neutral |
| 2024-07-19 | Fortgesetzt | Jefferies | Buy |
| 2023-10-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-10 | Hochstufung | UBS | Sell → Neutral |
| 2022-11-08 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Fortgesetzt | Jefferies | Hold |
| 2022-06-14 | Eingeleitet | UBS | Sell |
| 2022-05-10 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Eingeleitet | Citigroup | Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-03-08 | Herabstufung | Goldman | Buy → Neutral |
| 2021-03-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Eingeleitet | Argus | Hold |
| 2020-12-14 | Eingeleitet | Bernstein | Mkt Perform |
Alle ansehen
Viatris Inc Aktie (VTRS) Neueste Nachrichten
Viatris Q1 2026 Earnings Preview: Caution remains around ongoing turnaround (VTRS:NASDAQ) - Seeking Alpha
Viatris CFO leaving Canonsburg pharma giant - WPXI
Are Wall Street Analysts Bullish on Viatris Stock? - Barchart
Viatris To Go Ex-Dividend On May 22nd, 2026 With 0.12 USD Dividend Per Share - Moomoo
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris Gears Up to Report Q1 Earnings: What's in the Cards? - Yahoo Finance
Viatris Names Paul Campbell Interim CFO as Doretta Mistras Announces Departure - citybiz
Maryland reaches $4.5 million settlement with EpiPen makers - Baltimore Sun
Edwards names Theodora Mistras as CFO - MedTech Dive
Davis Selected Advisers (NASDAQ: VTRS) reports 78.21M shares, 6.8% stake - Stock Titan
MSN Money - MSN
Avoiding Lag: Real-Time Signals in (VTRS) Movement - Stock Traders Daily
Viatris declares $0.12 quarterly dividend per share - Investing.com
Viatris declares $0.12 quarterly dividend per share By Investing.com - Investing.com Canada
Viatris sets June 17 payment for $0.12 a share quarterly dividend - Stock Titan
Viatris Announces Quarterly Dividend - ChartMill
Viatris Announces CFO Transition: Theodora Mistras Departs, Paul Campbell Appointed Interim CFO - Minichart
Viatris declares $0.12 quarterly dividend payable June 17, 2026. - Pluang
Viatris CFO to depart; interim CFO named - MSN
Viatris Names Paul Campbell Interim Chief Financial Officer - TipRanks
Viatris Announces Chief Financial Officer Transition - The Malaysian Reserve
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
Viatris CFO Doretta Mistras to leave, Paul Campbell named interim By Investing.com - Investing.com Australia
Edwards Lifesciences Announces Appointment of CFO - Business Wire
Viatris (Nasdaq: VTRS) appoints Paul Campbell as interim CFO - Stock Titan
Earnings Preview: Viatris to Report Financial Results Pre-market on May 07 - Moomoo
Viatris Contraceptive Patch Data Puts Women’s Health Growth Story In Focus - Sahm
Is It Too Late To Consider Viatris (VTRS) After Its Strong One Year Share Price Run - Yahoo Finance
Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune
VTRS SEC FilingsViatris Inc Ord Shs 10-K, 10-Q, 8-K Forms - Stock Titan
Viatris presents data on low-dose contraceptive patch at ACOG By Investing.com - Investing.com India
Viatris presents data on low-dose contraceptive patch at ACOG - Investing.com
Weekly birth control patch data gets 6 slots at major OB-GYN meeting - Stock Titan
Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting - ChartMill
Is Viatris (VTRS) One of the Best Medical Stocks to Buy Under $30? - Insider Monkey
Vanguard discloses 7.36% stake in Viatris (NASDAQ: VTRS) - Stock Titan
Merz Gets 2 More Months To Block Generic MS Drug - Law360
Viatris (VTRS) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Viatris Inc Profile: Summary - OpenSecrets
Trazodone Market Growth Size 2026, Trends, Industry Analysis, - openPR.com
Viatris Inc. (VTRS) Stock Analysis: Exploring Potential Gains With A 7.76% Upside - DirectorsTalk Interviews
Does Xanax XR Recall Over Dissolution Issues Change The Bull Case For Viatris (VTRS)? - simplywall.st
Viatris gains as UBS upgrades to buy on outlook and pipeline - MSN
Viatris shares break six-session winning streak - MSN
Viatris Inc. stock rises Friday, outperforms market - MSN
VTRS Price Today: Viatris Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Discipline and Rules-Based Execution in VTRS Response - Stock Traders Daily
Viatris in charts: Generic sales drop 16% in Q1; revenue from Developed Markets falls 13% - MSN
Viatris Inc. stock rises Thursday, outperforms market - MarketWatch
Finanzdaten der Viatris Inc-Aktie (VTRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
8.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):